15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Atea Pharmaceuticals Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $10.00 to $10.00, so the covering firms are broadly aligned. The average target of $10.00 sits 122% above the current $4.50. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.55 next quarter toward $-1.39 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Atea Pharmaceuticals Inc.
As of Jul, 1 of 1 firms rate AVIR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AVIR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.55
Range $-0.58 – $-0.51 · 2 analysts · +3% YoY
Next period, 2 analysts expect Atea Pharmaceuticals Inc to earn $-0.55 a share (range $-0.58 – $-0.51), versus $-0.53 a year earlier. Full-year consensus is $-1.93, growing to $-1.39 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $30.2M next year.
Top analysts covering Atea Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AVIR.
#1
Matthew Harrison
Morgan Stanley · Rank #243
Hold
$6.00+33.2% to target
Overall win rate
44%
+ Follow
#2
UR
Umer Raffat
Evercore ISI
Buy
$10.00+122.0% to target
Coverage
—
+ Follow
#3
JM
Jonathan Miller
Evercore ISI
Buy
$10.00+122.0% to target
Coverage
—
+ Follow
AVIR stock forecast FAQ
What is AVIR's average 12-month price target?+
The 1 analysts with a live target average $10.00 for Atea Pharmaceuticals Inc over the next 12 months, ranging from a $10.00 high to a $10.00 low.
Is AVIR stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover AVIR?+
1 analysts have an active rating on Atea Pharmaceuticals Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering AVIR?+
Among analysts who currently cover AVIR, Matthew Harrison of Morgan Stanley has the strongest overall Quantellect track record (Rank #243). Their current call is Hold with a $6.00 target.
What is Atea Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.55 per share (range $-0.58 – $-0.51) across 2 analysts. Full-year EPS is projected at $-1.93, rising to $-1.39 the following year.
How much revenue is Atea Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $30.2M next year.
Have analysts been upgrading or downgrading AVIR lately?+
As of Jul, 1 of 1 firms rate AVIR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AVIR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
